Crystera

Crystera is a biotechnology company specializing in structure-based drug discovery (SBDD) to develop innovative small molecule therapeutics. Leveraging advanced X-ray crystallography and protein engineering, the company focuses on challenging targets in oncology, metabolic disorders, and inflammatory diseases. Crystera's platform enables the precise design of high-affinity ligands for proteins that were previously considered undruggable. The company is headquartered in Suzhou, China, and maintains a pipeline of candidates, including inhibitors for SHP2 and KRAS, aimed at addressing significant unmet medical needs in cancer treatment. By integrating structural biology with medicinal chemistry, Crystera aims to accelerate the transition from target identification to clinical development.